• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖蛋白 3 与甲胎蛋白作为肝细胞癌血清标志物的比较:一项荟萃分析。

A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.

机构信息

Institute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, Chongqing 400038, People's Republic of China.

出版信息

J Cancer Res Clin Oncol. 2013 Aug;139(8):1417-24. doi: 10.1007/s00432-013-1458-5. Epub 2013 Jun 7.

DOI:10.1007/s00432-013-1458-5
PMID:23743582
Abstract

BACKGROUNDS

Glypican-3(GPC3) has been reported as one of the most promising serum markers for hepatocellular carcinoma (HCC), while several studies have conflicting results for the diagnostic accuracy between GPC3 and alpha-fetoprotein (AFP).

METHODS

Studies that explored the diagnostic value of GPC3 and AFP in HCC were searched in MEDLINE, EMBASE, PUBMED, the Cochrane Library and Chinese biomedical literature database (CBM). Sensitivity, specificity and other measures about the accuracy of serum GPC3 and AFP in the diagnosis of HCC were pooled using random effects models. Summary receiver operating characteristic curve (sROC) analysis was used to summarize the overall test performance.

RESULTS

Ten studies were included in our meta-analysis. The pooled sensitivity for AFP and GPC3 is 51.9% (95% confidence interval (CI) 0.47-0.56) and 59.2% (95% CI 0.55-0.63), respectively, while the pooled specificity for AFP and GPC3 is 94% (95% CI 92.1-95.6%) and 84.8% (95% CI 82-87.3%), respectively. The pooled diagnostic odds ratio (DOR) for AFP and GPC3 were 23.4 (95% CI 10.3-53.2) and 17.99 (95% CI 5.4-60.4), respectively. Area under sROC for both AFP and GPC3 is 0.81 (95% CI 0.77-0.84).

CONCLUSIONS

GPC3 is comparable to AFP as a serum marker for the diagnosis of HCC, combination of AFP and GPC3 can elevate the sensitivity of diagnosis.

摘要

背景

磷脂酰聚糖-3(GPC3)已被报道为肝细胞癌(HCC)最有前途的血清标志物之一,而几项研究对 GPC3 和甲胎蛋白(AFP)之间的诊断准确性存在相互矛盾的结果。

方法

在 MEDLINE、EMBASE、PUBMED、Cochrane 图书馆和中国生物医学文献数据库(CBM)中搜索了探讨 GPC3 和 AFP 对 HCC 诊断价值的研究。使用随机效应模型汇总血清 GPC3 和 AFP 对 HCC 诊断准确性的灵敏度、特异性和其他指标。汇总受试者工作特征曲线(sROC)分析用于总结整体测试性能。

结果

我们的荟萃分析纳入了 10 项研究。AFP 和 GPC3 的合并灵敏度分别为 51.9%(95%置信区间(CI)0.47-0.56)和 59.2%(95% CI 0.55-0.63),而 AFP 和 GPC3 的合并特异性分别为 94%(95% CI 92.1-95.6%)和 84.8%(95% CI 82-87.3%)。AFP 和 GPC3 的合并诊断比值比(DOR)分别为 23.4(95% CI 10.3-53.2)和 17.99(95% CI 5.4-60.4)。AFP 和 GPC3 的 sROC 曲线下面积分别为 0.81(95% CI 0.77-0.84)。

结论

GPC3 可与 AFP 一样作为 HCC 的血清标志物,联合使用 AFP 和 GPC3 可提高诊断的灵敏度。

相似文献

1
A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.糖蛋白 3 与甲胎蛋白作为肝细胞癌血清标志物的比较:一项荟萃分析。
J Cancer Res Clin Oncol. 2013 Aug;139(8):1417-24. doi: 10.1007/s00432-013-1458-5. Epub 2013 Jun 7.
2
Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis.甲胎蛋白 L3 在肝细胞癌中的应用:一项荟萃分析。
Clin Chim Acta. 2013 Oct 21;425:212-20. doi: 10.1016/j.cca.2013.08.005. Epub 2013 Aug 13.
3
Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis.高尔基蛋白 73 与甲胎蛋白联合检测对原发性肝癌的诊断价值:一项荟萃分析。
BMC Cancer. 2012 Jan 16;12:17. doi: 10.1186/1471-2407-12-17.
4
Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis.血清磷脂酰肌醇蛋白聚糖-3在肝细胞癌患者中的诊断准确性:一项Meta分析的系统评价
Arch Med Res. 2014 Oct;45(7):580-8. doi: 10.1016/j.arcmed.2014.11.002. Epub 2014 Nov 13.
5
Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.血清 Glypican 3 在肝细胞癌诊断中的性能:一项荟萃分析。
Ann Hepatol. 2019 Jan-Feb;18(1):58-67. doi: 10.5604/01.3001.0012.7863.
6
Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis.丙型肝炎患者中检测肝细胞癌的甲胎蛋白检测特征。一项系统评价与批判性分析。
Ann Intern Med. 2003 Jul 1;139(1):46-50. doi: 10.7326/0003-4819-139-1-200307010-00012.
7
Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma.血清甲胎蛋白与LI-RADS v2018联合应用对钆塞酸增强MRI在肝细胞癌诊断和预后评估中的作用
Eur Radiol. 2025 Feb 10. doi: 10.1007/s00330-025-11418-2.
8
Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study.利用术前甲胎蛋白和异常凝血酶原水平对肝细胞癌预后进行聚类分析:一项多机构研究
J Gastrointest Surg. 2025 Apr;29(4):101980. doi: 10.1016/j.gassur.2025.101980. Epub 2025 Jan 28.
9
First trimester serum tests for Down's syndrome screening.孕早期唐氏综合征筛查的血清学检测
Cochrane Database Syst Rev. 2015 Nov 30;2015(11):CD011975. doi: 10.1002/14651858.CD011975.
10
Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis.Ras 相关结构域家族 1A 启动子甲基化与肝细胞癌的相关性:一项荟萃分析。
World J Gastroenterol. 2013 Nov 7;19(41):7189-96. doi: 10.3748/wjg.v19.i41.7189.

引用本文的文献

1
Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges.肝细胞癌的免疫治疗与肝移植:当前及未来挑战
World J Transplant. 2025 Jun 18;15(2):98509. doi: 10.5500/wjt.v15.i2.98509.
2
A transformer-based deep learning survival prediction model and an explainable XGBoost anti-PD-1/PD-L1 outcome prediction model based on the cGAS-STING-centered pathways in hepatocellular carcinoma.一种基于变压器的深度学习生存预测模型和一种基于肝细胞癌中以cGAS-STING为中心的通路的可解释XGBoost抗PD-1/PD-L1疗效预测模型。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbae686.
3
Differences in Prediagnostic Serum Metabolomic and Lipidomic Profiles Between Cirrhosis Patients with and without Incident Hepatocellular Carcinoma.

本文引用的文献

1
Hepatocellualar carcinoma serum markers.肝细胞癌血清标志物。
Semin Oncol. 2012 Aug;39(4):410-33. doi: 10.1053/j.seminoncol.2012.05.001.
2
Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.同时检测血清甲胎蛋白、磷脂酰肌醇蛋白聚糖-3和人宫颈癌基因产物(HCCR)以诊断肝细胞癌。
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1718-24. doi: 10.5754/hge11124. Epub 2011 Jul 15.
3
Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.血清磷脂酰聚糖 3 在肝细胞癌患者中的诊断和预后作用。
肝硬化伴发与未伴发肝细胞癌患者诊断前血清代谢组学和脂质组学特征的差异
J Hepatocell Carcinoma. 2024 Sep 7;11:1699-1712. doi: 10.2147/JHC.S474010. eCollection 2024.
4
Biomarker in Hepatocellular Carcinoma.肝细胞癌中的生物标志物
Indian J Surg Oncol. 2024 May;15(Suppl 2):261-268. doi: 10.1007/s13193-023-01858-x. Epub 2024 Jan 2.
5
Serum tRF-33-RZYQHQ9M739P0J as a novel biomarker for auxiliary diagnosis and disease course monitoring of hepatocellular carcinoma.血清tRF-33-RZYQHQ9M739P0J作为肝细胞癌辅助诊断和病程监测的新型生物标志物。
Heliyon. 2024 Apr 20;10(9):e30084. doi: 10.1016/j.heliyon.2024.e30084. eCollection 2024 May 15.
6
Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma.肝细胞癌的新兴及临床认可的生物标志物
Cancers (Basel). 2024 Apr 10;16(8):1453. doi: 10.3390/cancers16081453.
7
Combination of serum alpha-fetoprotein, PIVKA-Ⅱ and glypican-3 in diagnosis of hepatocellular carcinoma: a meta-analysis.血清甲胎蛋白、异常凝血酶原和磷脂酰肌醇聚糖蛋白 3 联合检测在肝细胞癌诊断中的价值:一项荟萃分析。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Feb 1;53(1):131-139. doi: 10.3724/zdxbyxb-2023-0483.
8
Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.肾型谷氨酰胺酶是肝细胞癌诊断和预后的生物标志物:一项前瞻性研究。
BMC Cancer. 2023 Nov 9;23(1):1081. doi: 10.1186/s12885-023-11601-y.
9
A high preoperative serum IL-25 level is a negative prognosis predictor after liver resection for HBV-HCC.术前血清白细胞介素-25水平升高是乙肝相关肝细胞癌肝切除术后的负性预后预测指标。
Front Oncol. 2022 Sep 2;12:858151. doi: 10.3389/fonc.2022.858151. eCollection 2022.
10
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma.循环生物标志物在肝细胞癌的诊断和治疗中的应用。
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):670-681. doi: 10.1038/s41575-022-00620-y. Epub 2022 Jun 8.
J Clin Lab Anal. 2011;25(5):350-3. doi: 10.1002/jcla.20484.
4
Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.癌胚抗原糖蛋白 3 作为肝细胞癌有前途的早期诊断标志物。
Hepatobiliary Pancreat Dis Int. 2011 Jun;10(3):289-94. doi: 10.1016/s1499-3872(11)60048-9.
5
[Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].[磷脂酰肌醇蛋白聚糖-3在肝细胞癌中的表达特征及其诊断与鉴别诊断价值]
Zhonghua Gan Zang Bing Za Zhi. 2011 Apr;19(4):260-5. doi: 10.3760/cma.j.issn.1007-3418.2011.04.008.
6
Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.应用多重荧光定量 RT-PCR 检测肝癌患者外周血中甲胎蛋白和高尔基糖蛋白-3 mRNA。
J Clin Lab Anal. 2011;25(2):113-7. doi: 10.1002/jcla.20443.
7
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
8
Up-regulation of glypican-3 in human hepatocellular carcinoma.糖蛋白聚糖-3 在人肝细胞癌中的上调。
Anticancer Res. 2010 Dec;30(12):5055-61.
9
[Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma].[血清磷脂酰肌醇蛋白聚糖-3作为肝细胞癌和恶性黑色素瘤肿瘤标志物的评估]
Nihon Rinsho. 2010 Jul;68 Suppl 7:833-6.
10
Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.血清和肝组织中高尔基糖蛋白 3 对原发性肝细胞癌的诊断价值。
World J Gastroenterol. 2010 Sep 21;16(35):4410-5. doi: 10.3748/wjg.v16.i35.4410.